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Abstract: Retinoblastoma is a malignant tumour of the retina which most often occurs in children.
Earlier studies on retinoblastoma have concentrated on the identification of key players in the disease
and have not provided information on activated/inhibited signalling pathways. The dysregulation
of protein phosphorylation in cancer provides clues about the affected signalling cascades in cancer.
Phosphoproteomics is an ideal tool for the study of phosphorylation changes in proteins. Hence,
global phosphoproteomics of retinoblastoma (RB) was carried out to identify signalling events
associated with this cancer. Over 350 proteins showed differential phosphorylation in RB compared
to control retina. Our study identified stress response proteins to be hyperphosphorylated in RB which
included H2A histone family member X (H2AFX) and sirtuin 1. In particular, Ser140 of H2AFX also
known as gamma-H2AX was found to be hyperphosphorylated in retinoblastoma, which indicated
the activation of DNA damage response pathways. We also observed the activation of anti-apoptosis
in retinoblastoma compared to control. These observations showed the activation of survival
pathways in retinoblastoma. The identification of hyperphosphorylated protein kinases including
Bromodomain containing 4 (BRD4), Lysine deficient protein kinase 1 (WNK1), and Cyclin-dependent
kinase 1 (CDK1) in RB opens new avenues for the treatment of RB. These kinases can be considered
as probable therapeutic targets for RB, as small-molecule inhibitors for some of these kinases are
already in clinical trials for the treatment other cancers.
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1. Introduction
Phosphorylation is one of the major post-translational modifications of proteins that regulates
many cellular processes, including cellular communication, proliferation, differentiation, and survival.
This is emphasized by the fact that about one third of all eukaryotic proteins are phosphorylated
at some point [1]. Protein phosphorylation is governed by the coordinated function of kinases and
phosphatases. Dysregulated kinase signalling is observed in many diseases, including cancer [2].
Kinases are the key phosphoproteins, as they are central in various cellular signalling processes.
There are 518 kinases identified in the human genome [3], and studying the kinome map under
diseased conditions has become a research focus in the last decade.
Several methods are used for studying phosphoproteomics and deducing signalling networks,
such as antibody-based arrays [4], mass spectrometry [5,6], and flow mass-cytometry [7]. Due to the
limited availability of antibodies for phosphoproteins, mass spectrometry has emerged as the most
prominent technology for analysing kinome-regulated signalling networks [8,9]. Phosphoproteomics
is an emerging tool in the study of cancer for the identification of potential biomarkers and potential
therapy targets [10–12]. Phosphoproteomic approaches have identified targets for early screening and
therapy in hepatitis C virus (HCV)-mediated hepatocellular carcinoma [13]. Phosphoproteomics
has been applied to understanding disease progression and therapy in breast, lung, and brain
cancers [14–16].
Retinoblastoma (RB) is a childhood retinal cancer, with an incident rate of about 1 in 15,000–18,000
live births. RB occurs due to the lack of a functional RB1 gene, usually resulting in enucleation
in developing countries due to the diagnosis of the disease at later stages. Studying the disease
progression of RB using omics approaches and identifying novel therapeutic targets has recently been
a primary research focus. Genomic, genetic, and epigenetic changes have been studied widely to
characterize RB tumours in studies which concentrated on mutations, differential gene expression,
methylation changes, and deregulated miRNAs in RB [17]. These studies evaluated differentially
expressed genes in RB, leading to the identification of candidate oncogenes and tumour suppressors
involved in the progression of retinoblastoma. Some of these genes were also proposed as potential
therapeutic and prognostic targets. However, these studies did not focus on the signalling pathways
activated in RB. Protein phosphorylation is a critical determinant of signal transduction pathways.
We carried out a pilot quantitative phosphoproteomics study of primary RB tumour tissues and control
retina to identify crucial proteins in the signal transduction pathways of RB. This study identifies the
phosphorylated proteins in human retina for the first time in addition to specific sites that are regulated
in retinoblastoma. This study should help as an initiation factor for subsequent studies to investigate
and identify molecular mechanisms governing RB progression and identify novel biomarkers and
therapy options for retinoblastoma.
2. Results
2.1. Phosphoproteome of Human Retina
The phosphoproteome of the human retina has not been studied thus far. Phosphoproteomic
analysis of retinoblastoma and retina identified 1393 proteins that were phosphorylated in both
tissues. These phosphoproteins (irrespective of their differential expression status) were represented
by 2568 unique phosphopeptides containing 3476 phosphosites. The frequency of the identified
phosphorylated sites was Ser (91%), Thr (8%), and Tyr (1%).
To obtain insight into signalling events occurring in retina, phosphorylated proteins identified
in both retina and retinoblastoma were analysed by the DAVID tool (https://david.ncifcrf.gov/).
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The phosphoproteome revealed an enrichment of pathways involved in spliceosome, tight junction,
and insulin signalling (Table 1). Important mediators of the insulin pathway such as Akt, BCL-2
antagonist of cell death (BAD), FOXO1, and FASN were found to be phosphorylated in both retina and
retinoblastoma tissues (Figure 1). Tight junction proteins, which play a major role in the formation of
the blood retinal barrier, were also found to be phosphorylated.
Table 1. Pathways found to be enriched in retina and retinoblastoma (RB).
Pathways Genes Count p-Value
Spliceosome
NCBP1, TRA2B, PPIL1, U2AF2, TRA2A, HSPA1A, SART1,
SF3B2, CTNNBL1, HNRNPA3, SF3B1, DDX46, HNRNPK,
DDX23, RBM8A, PCBP1, USP39, DHX16, SNRNP70, ACIN1,
HNRNPC, PRPF40B, RBM25, PRPF40A, DDX42, PRPF31,
PRPF3, SNW1, SF3A1, HNRNPA1, HNRNPU, SNRNP200,
SLU7, THOC2, PRPF38B, RBM17, THOC1, PRPF38A
38 4.47 × 10−14
Tight junction
PARD3, CASK, CLDN11, PTEN, TJAP1, MYL9, CTTN, MLLT4,
AKT2, PRKCA, SYMPK, EPB41, MPDZ, PRKCI, MYH9,
PRKCE, CTNNA1, CTNNA2, PRKCB, EPB41L2, EPB41L3, TJP1,
EPB41L1, MYH14, TJP3, TJP2, SPTAN1, MYH10
28 8.77 × 10−7
Insulin signalling pathway
PHKB, FOXO1, PPP1R3D, PRKAR2B, PRKAR2A, SORBS1,
GYS1, FASN, PRKACA, PRKAA1, PRKACB, AKT2, MAP2K1,
BRAF, ACACA, PRKCI, PRKAB1, RAF1, BAD, MAPK1, CRKL,
PRKAR1B, TSC2, PRKAR1A, MAPK3, CRK, LIPE
27 3.44 × 10−6
Fc gamma R-mediated phagocytosis
PRKCA, DNM3, DNM1L, MAP2K1, SPHK2, LYN, MARCKSL1,
ASAP2, ASAP1, RAF1, PRKCE, AMPH, PRKCB, MAPK1,
CRKL, MAPK3, CFL1, MARCKS, PAK1, CRK, AKT2
21 1.20 × 10−5
ErbB signalling pathway
PRKCA, EGFR, MAP2K1, BRAF, CAMK2G, RAF1, BAD,
PRKCB, MAPK1, CRKL, PAK2, PAK4, NCK1, MAPK3,
CAMK2D, PAK1, CRK, ABL2, AKT2
19 4.20 × 10−5
2.2. Differentially Phosphorylated Proteins in Retinoblastoma
After identifying the signalling pathways present in both retina and retinoblastoma, we focused
our analysis on phosphoproteins that are differentially phosphorylated in RB compared to retina.
The analysis identified about 508 phosphosites corresponding to 361 unique proteins that were
differentially phosphorylated. Phosphorylated peptides with a fold change of 1.5 in at least three
tumour samples were considered to be differentially phosphorylated. We found 158 proteins to be
hyperphosphorylated and 203 proteins to be hypophosphorylated in retinoblastoma compared to
control retina (Supplementary Tables S2 and S3).
2.3. Categorization of Differentially Phosphorylated Proteins Based on Gene Ontology (GO) Annotation
Differentially phosphorylated proteins were categorized based on biological processes based
on GO annotation to identify the processes activated in retinoblastoma. Hyperphosphorylated
proteins were found to be involved in biological processes such as chromosome organization (14%),
RNA processing including splicing and transcription (14%), regulation of RNA metabolism (14%),
cellcycle (7%), and cellular response to stress (9%) (Figure 2A). Hypophosphorylated proteins were
found to be involved in the phosphate metabolic process, cytoskeleton organization, the glucose
metabolic process, and cell death (Figure 2B).
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Figure 2. Biological processes enriched in (A) hyperphosphorylated proteins and (B) hypophosphorylated
proteins of RB. Gene ontology (GO) analysis of hyperphosphorylated proteins identified various
biological processes requ red for active c ll proliferation such as cell cycle, transcription,
and chromosome organization. Biological processes such as cell death and neuron differentiation
were found in hypophosphorylated proteins analysis.
2.4. Phosphorylated Motifs Identified in Retinoblastoma
The analysis of sequences surrounding phosphorylation sites enabled the identification of
phosphorylation motifs for protein kinases. Each kinase scans the target protein sequences for a
specific motif and phosphorylates aspecific residue. The identification of phosphorylated motifs is
necessary in order to identify the activated upstream kinases, which can then be targeted using kinase
inhibitors to treat the disease.
Among the hyperphosphorylated proteins, motifs such as .......SP......, .......S.E....., .......S.D.....,
....R..SP...... and .......S.EE.... were identified to be among the top five motifs phosphorylated by
kinases (Figure 3). We then carried out NetworKIN analysis to find out the probable upstream
kinase of motifs enriched in phosphoproteins identified in retinoblastoma. The probable upstream
kinase of the hyperphosphorylated motif “.......SP......” was found to be cyclin-dependent kinases
Molecules 2018, 23, 1454 6 of 14
(CDKs). We found CDK1 and CDK11 cyclin-dependent kinases to be hyperphosphorylated in
retinoblastoma, indicating their activation. These activated kinases can be targeted using kinase
inhibitors for retinoblastoma treatment. Several CDK inhibitors are available for cancer treatment.
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Figure 3. otif analysis of hyperphosphorylated and hypophosphorylated proteins in RB.
Motif analysis identified a proline-directed phosphorylation motif, aspartate and glutamate
(acidic aminoacid) directed phosphorylation motifs to be enriched in hyperphosphorylated proteins.
2.5. Phosphorylated Kinases Identified in Retinoblastoma
Signalling pathways mediated by kinases regulate various hallmark processes in cancer, such as
cell cycle progression, angiogenesis, and metastasis. In the past decade, several small-molecule
inhibitors have been developed to target key kinases in cancers for therapeutic use. We attempted
to identify activated kinases in retinoblastoma, as this would either allow RB researchers to choose
already-available ki ase inhibitors for the treatment of other cancers or those which can be easily
tested in vitro using commercial librarie of kinase inhibitors. Among the differentially regulated
phosphoprote s, w identified ten kinases to be hyperphosphorylated, i cludi cyclin-dependant
kinases, serine/threo in prot in kinas WNK1, TNIK (TRAF2 and NCK-interacting protein kinase),
calcium/calmodulin-dependent serine threonine kinase (CASK), discs large MAGUK scaffold pr tein
3 (DLG3), BRD4, and BAZ1B (Table 2). Several of the identified kinases belong to the class of Ser/Thr
kinases and are localized to different compartments of the cell. A Tyr kinase, BAZ1B, was identified
that has both nuclear and cytoplasmic localization. Representative spectra of the phosphopeptides
corresponding to hyperphosphorylated kinases are presented in Figure 4.
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Table 2. List of kinases identified to be hyperphosphorylated in retinoblastoma.
# Gene Symbol Kinase Ser/Thr/Tyr Kinase PrimaryLocalization Available Drugs
1 CDK1 Cyclin-dependentkinase 1 Ser/Thr protein kinase Cytoplasm
Flavopiridol, dinaciclib,
PD0332991 [18]
2 CDK11B Cyclin-dependentkinase 11B Ser/Thr protein kinase
Cytoplasm;
Nucleus
Proposed target for cancer
treatment [19]
3 WNK1 Lysine deficientprotein kinase 1 Ser/Thr protein kinase Cytoplasm
Proposed target for cancer
treatment [20,21]
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Gene expression studies, copy number variation analysis, and epigenetic profiling including
miRNA and methylation of retinoblastoma were carried out to understand the disease mechanism
and key players in RB leading to tumour progression. The caveat of these studies is that they do
not provide information on activated/inhibited signalling pathways. Hence, we carried out a pilot
study on differential phosphoproteomic analysis of retinoblastoma to understand the signalling
mechanisms in this cancer. This is the first comprehensive phosphoproteomic analysis of retina
and retinoblastoma. Among 1393 proteins identified to be phosphorylated, about 350 proteins were
found to be differentially phosphorylated in retinoblastoma compared to normal retina, indicating
the retention of a retina-specific signalling signature in addition to tumour-related alterations in
cell signalling.
The insulin signalling pathway was found to be enriched in retina and retinoblastoma tissues.
In retina, the insulin pathway is active as apro-survival pathway. Particularly, we identified Akt,
FOXO1, and BAD to be phosphorylated in retina and retinoblastoma tissues. Previous studies in
retina and neurons identified insulin-regulated Akt to play a major role in cell survival compared
to the generally known nutrition storage function of the pathway [25]. It has been established that
Akt-mediated phosphorylation of BAD promotes cell survival [26]. We identified the phosphorylation
of BAD in retina and retinoblastoma, showing its prominent role in the survival of retina. Targeted
studies on retinoblastoma mouse models showed that Rb1 loss and additional oncogenic stress
including PTEN loss led to the activation of Akt and the subsequent inactivation of FOXO1, leading to
tumour proliferation. On the other hand, in normal retina of mouse models, p-Akt and p-FOXO1
signalling ceased proliferation [27]. Thus, the activation of the insulin signalling pathway had different
roles in retina and retinoblastoma.
Functional annotation of hyperphosphorylated proteins found the cellular response to stress to be
activated in retinoblastoma. Stress response proteins that were identified to be hyperphosphorylated
in retinoblastoma compared to control retina tissues included H2AFX, SIRT1, TNIK, WRNIP1, BAZ1B,
and CDK1. H2AFX is a replication-independent histone that contains a histone H2A domain and
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an SQ-motif. The phosphorylation of H2AFX at Ser140 is denoted as gamma-H2AX and is critical
during DNA double strand break signalling. This phosphorylation event helps in the recruitment
of repair proteins to carryout repair processes. We identified Ser140 to be hyperphosphorylated in
retinoblastoma tissues, indicating the role of H2AFX in signalling DNA damage to recruit repair
proteins to the site of damage [28]. We identified the phosphorylation of other proteins which help
in sustaining the phosphorylation of H2AFX. For example, HMGA2 protein was found to increase
the phosphorylation of H2AFX at serine 140, which is increased by the breakage of double-stranded
DNA. We observed the hyperphosphorylation of HMGA2 at Ser101 and Thr150 in retinoblastoma.
Similarly, SIRT1, a NAD+ dependent protein deacetylase is required for initial phosphorylation of
H2AX [29]. We identified the hyperphosphorylation of SIRT1 at Ser27. The hyperphosphorylation of
these proteins is indicative of the activation of the repair system in response to DNA damage usually
observed during tumour progression.
Apart from cellular stress response proteins, cell cycle proteins such as CDK1, CDK11, MCM2,
MCM3, MCM5, and CCNB1 were also found to be hyperphosphorylated in retinoblastoma, implicating
accelerated cell cycle progression. Besides, we identified DEK protein to be hyperphosphorylated in
retinoblastoma. DEK is localized in chromosome 6p, the region frequently observed to be amplified
in retinoblastoma, which also encompasses another oncogene (E2F3) [30]. It has been reported that
promoter region of DEK has specific E2F binding sites, indicating that DEK is transcriptionally activated
by E2F. In our study, DEK was identified to be hyperphosphorylated at Ser 306 position, the site that
lies in the multimerization and DNA binding domain of DEK [31]. Draper et al. have shown the role
of DEK in regulating apoptosis and senescence in primary human foreskin, HeLa, and osteosarcoma
cell line SAOS-2. We can envisage a similar role of regulating apoptosis by DEK in retinoblastoma [32].
Proteins that play a prominent role in the regulation of apoptosis were hypophosphorylated in
retinoblastoma compared to retina, indicating a reduction in cell death and favouring tumour cell
progression. We observed the hypophosphorylation of proapoptotic proteins including BAD, BCL2L13,
NGFR, and ARHGEF6. BCL-2 antagonist of cell death (BAD) belongs to the Bcl-2 family of proteins
that regulate cell death machinery. It has been shown in earlier studies that the phosphorylation
of BAD at Ser-75 and Ser-118 promotes its binding to 14-3-3 protein. This binding arrests BAD
at cytoplasm, leading to the inhibition of BAD-dependent death [33–35]. We identified BAD to
be hypophosphorylated at Ser118 in retinoblastoma. Phosphoprotein enriched in astrocytes 15
(PEA15) is an antiapoptotic protein which is preferentially phosphorylated at Ser104 and Ser116.
PEA15 phosphorylated at Ser116 is reported to bind to FADD (Fas-associated death domain protein),
preventing FADD from activating apoptosis [36]. We identified hypophosphorylation at Ser116 of
PEA15, which implicates its role in inhibiting apoptosis. It is important to note that the retina is an
extension of the central nervous system, and these post-mitotic cells also inhibit apoptosis in order to
enable their long-term survival. Thus, proteins relevant to the inhibition of apoptosis were identified
to be hypophosphorylated in retinoblastoma compared to control. It has already been well established
that post-mitotic cells and cancer cells have parallel survival mechanisms.
More importantly, we identified activated kinases in retinoblastoma for which either preclinical
studies or clinical trials are available in other cancers (Table 2). WNK1 is a proposed oncogenic
kinase found to be mutated in colorectal adenocarcinoma and breast cancer, whose role in cancer is
not fully elucidated [21]. The role of WNK1 in angiogenesis, cell proliferation, and cell migration
is recently emerging [37]. WNK1 is the downstream target of VEGFR2 and AK3/PIK pathways,
resulting in angiogenesis [38]. The prominent role of WNK1 in proliferation has been shown in mouse
neural progenitor cells, where the downregulation of WNK1 resulted in decreased cell proliferation and
migration through activation of MAPK, ERK1/2, and/or ERK5 pathways [39]. In our study, WNK1 was
identified to be hyperphosphorylated in retinoblastoma. The substrates of WNK1 such as MAPK1,
OXSR1, STK39 (SPAK), and ANKS1A were identified to be phosphorylated in our study, but their
phosphorylation status was unchanged in retinoblastoma compared to control retina tissues. However,
OXSR1 was identified to be overexpressed over two-fold in our proteomics study on retinoblastoma
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(unpublished data). Dbouk et al. showed in vascular endothelial cells that WNK1-mediated OXSR1
and SPAK activation is essential for proliferation, chemotaxis, and invasion, signifying its role in
angiogenesis [40]. Based on the literature evidence, the role of WNK1 and its substrates is depicted
in Figure 5. Pertaining to its role in angiogenesis, WNK1 can be a probable therapeutic target
for retinoblastoma.
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TNIK belongs to the germinal centre kinase family, and its role in the c-Jun N-terminal kinase
pathway and the NF-κB pathway is well known [41]. Given its importance in regulating the Wnt
pathway, TNIK is considered as a druggable target in colorectal cancer. Small-molecule inhibitors
of TNIK have been developed t treat col rectal cancers [42]. Mebendazole, a familiar drug in
anti-h lminthic ailments, was found to possess anti-cancer properties in pre-clinical models of several
cancers, and s shown to nhibit the kinas activity of TNIK [22]. As a result, clin al trials are
underway us ng this drug or the treatment of glioblastoma and pa iatric glioma (ClinicalTrials.gov
Identifier: NCT01729260 and NCT01837862). Based on these results, TNIK can be considered as a
potential therapeutic target for retinoblastoma.
Bromodomain-containing protein 4 (BRD4) is an atypical Ser/Thr protein kinase that belongs
to the bromodomain- and extra-terminal domain (BET) family of transcriptional regulators.
BRD4 regulates transcription by recruiting nucleosome remodelling complexes and co-activators.
BRD4 is known to play an important role in cell cycle progression and has been found to be associated
with acetylated chromatin throughout the entire cell cycle. Small-molecule inhibitors of BET protein
are now available as treatment for several types of cancer [24].
This study serves as preamble for testing those kinase inhibitors in vitro retinoblastoma cell
lines and animal models. We believe that these hyperphosphorylated kinases are good targets for
therapeutic intervention in retinoblastoma, where targeted therapy has yet not been tried. In addition
to these, the present differential phosphoproteomic atlas should enable future molecular diagnostic
opportunities such as monitoring gamma-H2AX for disease progression after careful analysis of its
role in retinoblastoma.
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4. Materials and Methods
4.1. Tumour Samples and Lysate Preparation
The present study was approved by the institutional ethics board and conducted at the Medical
Research Foundation and Vision Research Foundation, Sankara Nethralaya, India, with Ethics
No. 247-2011-P. Control retinas from cadavers were collected from the C.U. SHAH eye bank,
Sankara Nethralaya, in the age group of 18–28 years. Tumour tissues were collected with informed
consent. The consent and approval to use the samples for research was obtained from the
parents/guardians of the patients. The tumour characteristics are given in Supplementary Table S1.
In the enucleated eye globe, a part of the tumour was collected for proteomic study, and the other part
was used for histopathological studies. The collected tumours were snap frozen in liquid nitrogen and
transferred to −80 ◦C until used for proteomic analyses. Two control retinas and four retinoblastoma
tumour tissues were pulverized by adding liquid nitrogen and homogenizing in a homogenizer.
The homogenized tissue was lysed by lysis buffers to the final concentration of 2% of SDS in 50 mM
Triethyl ammonium bicarbonate (TEABC), phosphatase inhibitors 1 mM sodium fluoride (NaF),
2.5 mM sodium pyrophosphate, 1 mM sodium orthovanadate, and 1 mM β-glycerophosphate.
4.2. Trypsin Digestion and Tandem Mass Tag (TMT) Labelling
Protein estimation was done by bicinchoninic acid (BCA) protein assay kit (Pierce, Waltham, MA, USA)
according to the manufacturer’s instructions. Equal amounts of protein (1.5 mg) from normal retina
and RB tumours were taken, and sulfhydryl bonds in cysteine were reduced by dithiothreitol (DTT) to
the final concentration of 5 mM, and incubated for 20 min at 60 ◦C. Buffer exchange was performed
three times to reduce the concentration of the SDS from 2% to <0.05% by 8M urea buffer in 30 kDa
MWCO filters (Millipore, Burlington, MA, USA). Alkylation was carried out with Iodoacetic acid
(IAA) to a final concentration of 20 mM for 10 min at room temperature in the dark. The urea in the
sample was further removed by buffer exchange with 50 mM TEABC. Digestion of the proteins was
performed with sequence-grade trypsin at a 1:20 ratio of trypsin to protein incubated overnight at
37 ◦C. Peptides were vacuum dried until further use.
For TMT labelling, 0.8 mg of protein was used from each sample. The TMT labels were thawed
on ice and reconstituted in 41 µL of anhydrous acetonitrile (ACN). The digested peptide samples
were reconstituted in 100 µL of TEABC (pH 8.0). TMT labels 126, 127C, 129C, and 130C were used for
labelling RB tumour samples, and TMT labels 129N and 130N were used for labelling control retina
samples. The reaction was incubated for 1 h at room temperature. After incubation, the reaction was
quenched with 8 µL of 5% hydroxylamine. The labelled peptides were lyophilized and stored until use.
4.3. Basic pH Reversed-Phase Liquid Chromatography (bRPLC) and TiO2-Based Phosphopeptide Enrichment
Fractionation of the peptides was carried out by bRPLC using XBridge C18, 5 µm, 250 × 4.6 mM
column (Waters Corp, Milford, MA, USA). The lyophilized peptides were reconstituted in 2 mL of
solvent A (7 mM TEABC pH 9.0). Fractionation was performed by increasing the gradient of solvent
B (7 mM TEABC in 90% ACN) on an Agilent 1100 Liquid Chromatography (LC) with a flow rate
of 1 mL/min. The fractions were collected in a 96-well plate with 1% formic acid added in the
wells. The collected fractions were dried, and to each of the fractions 400 µL of 80% ACN with 0.1%
Trifluoroacetic acid (TFA) was used to reconstitute the dried peptides. The fractions were concatenated
into 12 fractions and vacuum dried. TiO2-based phosphopeptide enrichment was carried out by
reconstituting the peptides in 5% DHB solution and mixing with TiO2 beads. The peptides and TiO2
beads were mixed in a proportion of 1:1 and incubated for 1 h at room temperature. The peptide-bead
mixture was centrifuged and saved for further analysis and washed twice with wash solution (3% TFA
in 80% ACN). The beads were resuspended in wash solution and transferred onto a stage tip with a
C18 plug. The beads were washed once with wash solution. The phospho-enriched peptides were
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eluted twice with 4% ammonium hydroxide into a collection tube containing 4% TFA. The enriched
peptides were vacuum dried and stored for downstream analysis.
4.4. LC MS/MS Analysis of the Enriched Phosphopeptides
The enriched phosphopeptides were analysed on an LTQ Orbitrap Elite mass spectrometer
(Thermo Scientific, Bremen, Germany) interfaced with an Easy nLC II nanoflow LC system.
The peptides were reconstituted in 0.1% formic acid and loaded onto the trap column (75 µm × 2 cm)
packed in-house with magic C18 AQ. The peptides were resolved using an analytical column
(75 µm × 20 cm), and the flow rate was adjusted to 350 nL/min with a linear gradient of 10–35%
solvent B (0.1% formic acid and 95% ACN) over 80 minutes. The sample loading and reconditioning
of the column was done for 40 minutes, taking the total run time of 120 minutes. Data-dependent
acquisition with full scans at 350–1700 m/z range was carried out using an Orbitrap mass analyser
at a mass resolution of 120,000 at 400 m/z. The fifteen most intense precursor ions were selected for
MS/MS fragmentation using high-energy collision-induced dissociation fragmentation (HCD) with
32% normalized collision energy and detected at a mass resolution of 30,000 at 400 m/z. Dynamic
exclusion was set for 30 s with a 10 ppm mass window. Internal calibration was carried out using lock
mass option (m/z 445.1200025) from ambient air.
4.5. Data Analysis
The Data analysis was performed on Proteome discoverer 1.4(1.4.0.288) (Thermo Fisher Scientific
Inc., Bremen, Germany) using Sequest and Mascot search engines. The data was searched
against the NCBI Human RefSeq protein database 65 containing71, 644 protein sequences (https:
//www.ncbi.nlm.nih.gov/refseq/). Fixed modification included in the search parameters were the
carbamidomethylation of cysteine, TMT 6-plex labels at the N-terminal of peptide (229.16 Da) and
lysine side chain (229.16 Da). N-terminal acetylation, oxidation of methionine, phosphorylation
at serine, threonine, and tyrosine (+79.966 Da), and were included in the algorithm as variable
modification. MS/MS were searched with a precursor mass tolerance of 10 ppm, and the fragment
mass tolerance was set to 0.05 Da. The protease used was specified as trypsin, and a maximum of two
missed cleavages were allowed. The data was searched against a target decoy database, and the false
discovery rate was set to 1% at the peptide level. The TMT ratio for each peptide–spectrum match
was calculated by the quantitation node, and the probability of phosphorylation for each Ser/Thr/Tyr
site was calculated by the phosphoRS3.1 node in the Proteome Discoverer. Only the phosphopeptides
with >75% site localization were considered for the analysis. The peptides with ratios of ≥1.5 in at
least three samples were considered as significant differentials and used for further data analysis.
MS/MS data associated with the study were submitted to the PRIDE database [43] and are available
via ProteomeXchange with identifier PXD007228.
4.6. Gene Ontology Analysis
Total phosphoproteins identified in the study were analysed by DAVID to identify the signalling
pathways enriched in retina. Pathways with p-values <0.05 were considered for discussion.
Gene ontology-based functional enrichment analysis was carried out using DAVID. The identified
differentially phosphorylated proteins were categorized based on biological process by carrying out
bioinformatic analysis using DAVID. Biological processes with at least ten proteins in one cluster for a
given GO term and p-values <0.05 were considered for discussion.
4.7. Motif Enrichment Analysis
Identified phosphopeptide sequences were formatted to 15-amino-acid sequences with the
phosphorylated residue in the central position and seven flanking amino acids. The residues lying in
N- and C- termini of the proteins were excluded from the analysis. The remaining peptides were used
for motif analysis using the motif-x v1.2 (http://motif-x.med.harvard.edu/) algorithm [44] for cases
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of serine, threonine, and tryptophan as the central amino acid. All human proteins were chosen as a
background database of proteins for significance analysis. Motifs supported by at least ten peptides
and p-value threshold of 1 × 10−6 were considered as enriched in this study.
4.8. Kinase–Substrate Network Analysis
Probable upstream kinases of phosphoproteins with enriched substrate motifs were identified
using NetworKIN 3.0 [45]. Offline version NetworKIN was run on a custom input file with protein
accessions, phosphorylation positions, and residues. Default parameters were used in NetworKIN
analysis and for filtering the results. Thus-identified kinase–substrate interactions were integrated
with motif results and differential status of phosphorylation for further analysis and interpretation.
Supplementary Materials: The following are available online. Table S1: Details of retinoblastoma samples used
in the study; Table S2: List of hyperphosphorylated peptides identified in retinoblastoma; Table S3: List of
hypophosphorylated peptides identified in retinoblastoma.
Author Contributions: L.D.N.S., R.D.—concept, data collection, data analysis and interpretation, manuscript
writing; A.K.M., V.N.P., G.J.S.—mass spectrometry data collection, in silico analysis; U.M.K., V.K., P.R.—provision
of experimental materials, manuscript editing; H.G., S.V.E., S.K., A.P., T.S.K.P. conceived, designed experiment,
contributed experimental materials, contributed to data interpretation and manuscript editing.
Funding: The study was supported by the Department of Biotechnology (DBT), Govt. of India under program
support for research on Retinoblastoma grant no. BT/01/CEIB/11/V/16. LDNS is a recipient of research
associateship from DBT. DST-SERB (EMR/2015/00607) to S.V.E.
Conflicts of Interest: The authors declare no conflict of interest. The funding sponsors had no role in the design
of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the
decision to publish the results.
References
1. Hubbard, M.J.; Cohen, P. On target with a new mechanism for the regulation of protein phosphorylation.
Trends Biochem. Sci. 1993, 18, 172–177. [CrossRef]
2. Cohen, P. The role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal
Lecture. Eur. J. Biochem. 2001, 268, 5001–5010. [CrossRef] [PubMed]
3. Manning, G.; Whyte, D.B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the
human genome. Science 2002, 298, 1912–1934. [CrossRef] [PubMed]
4. Haab, B.B. Antibody arrays in cancer research. Mol. Cell. Proteomics 2005, 4, 377–383. [CrossRef] [PubMed]
5. Olsen, J.V.; Blagoev, B.; Gnad, F.; Macek, B.; Kumar, C.; Mortensen, P.; Mann, M. Global, in vivo,
and site-specific phosphorylation dynamics in signaling networks. Cell 2006, 127, 635–648. [CrossRef]
[PubMed]
6. Mann, M.; Ong, S.E.; Gronborg, M.; Steen, H.; Jensen, O.N.; Pandey, A. Analysis of protein phosphorylation
using mass spectrometry: Deciphering the phosphoproteome. Trends Biotechnol. 2002, 20, 261–268. [CrossRef]
7. Krutzik, P.O.; Nolan, G.P. Intracellular phospho-protein staining techniques for flow cytometry: Monitoring
single cell signaling events. Cytom. Part A J. Int. Soc. Anal. Cytol. 2003, 55, 61–70. [CrossRef] [PubMed]
8. Nita-Lazar, A. Quantitative analysis of phosphorylation-based protein signaling networks in the immune
system by mass spectrometry. Wiley Interdiscip. Rev. Syst. Biol. Med. 2011, 3, 368–376. [CrossRef] [PubMed]
9. White, F.M.; Wolf-Yadlin, A. Methods for the Analysis of Protein Phosphorylation-Mediated Cellular
Signaling Networks. Annu. Rev. Anal. Chem. 2016, 9, 295–315. [CrossRef] [PubMed]
10. Rigbolt, K.T.; Blagoev, B. Quantitative phosphoproteomics to characterize signaling networks. Semin. Cell
Dev. Biol. 2012, 23, 863–871. [CrossRef] [PubMed]
11. Kosako, H.; Nagano, K. Quantitative phosphoproteomics strategies for understanding protein
kinase-mediated signal transduction pathways. Expert Rev. Proteom. 2011, 8, 81–94. [CrossRef] [PubMed]
12. Ashman, K.; Villar, E.L. Phosphoproteomics and cancer research. Clin. Transl. Oncol. 2009, 11, 356–362.
[CrossRef] [PubMed]
Molecules 2018, 23, 1454 13 of 14
13. Lu, N.T.; Liu, N.M.; Vu, J.Q.; Patel, D.; Cohn, W.; Capri, J.; Ziegler, M.; Patel, N.; Tramontano, A.; Williams, R.;
et al. Phospho-Network Analysis Identifies and Quantifies Hepatitis C Virus (HCV)-induced Hepatocellular
Carcinoma (HCC) Proteins Regulating Viral-mediated Tumor Growth. Cancer Genom. Proteom. 2016, 13,
339–357.
14. Narumi, R.; Murakami, T.; Kuga, T.; Adachi, J.; Shiromizu, T.; Muraoka, S.; Kume, H.; Kodera, Y.;
Matsumoto, M.; Nakayama, K.; et al. A strategy for large-scale phosphoproteomics and SRM-based
validation of human breast cancer tissue samples. J. Proteome Res. 2012, 11, 5311–5322. [CrossRef] [PubMed]
15. Lopez, E.; Cho, W.C. Phosphoproteomics and lung cancer research. Int. J. Mol. Sci. 2012, 13, 12287–12314.
[CrossRef] [PubMed]
16. Lescarbeau, R.S.; Lei, L.; Bakken, K.K.; Sims, P.A.; Sarkaria, J.N.; Canoll, P.; White, F.M. Quantitative
Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.
Mol. Cancer Ther. 2016, 15, 1332–1343. [CrossRef] [PubMed]
17. Theriault, B.L.; Dimaras, H.; Gallie, B.L.; Corson, T.W. The genomic landscape of retinoblastoma: A review.
Clin. Exp. Ophthalmol. 2014, 42, 33–52. [CrossRef] [PubMed]
18. Shapiro, G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 2006, 24,
1770–1783. [CrossRef] [PubMed]
19. Zhou, Y.; Shen, J.K.; Hornicek, F.J.; Kan, Q.; Duan, Z. The emerging roles and therapeutic potential of
cyclin-dependent kinase 11 (CDK11) in human cancer. Oncotarget 2016, 7, 40846–40859. [CrossRef] [PubMed]
20. Byrne, D.P.; Foulkes, D.M.; Eyers, P.A. Pseudokinases: Update on their functions and evaluation as new
drug targets. Future Med. Chem. 2017, 9, 245–265. [CrossRef] [PubMed]
21. Fleuren, E.D.; Zhang, L.; Wu, J.; Daly, R.J. The kinome ‘at large’ in cancer. Nat. Rev. Cancer 2016, 16, 83–98.
[CrossRef] [PubMed]
22. Tan, Z.; Chen, L.; Zhang, S. Comprehensive Modeling and Discovery of Mebendazole as a Novel TRAF2-
and NCK-interacting Kinase Inhibitor. Sci. Rep. 2016, 6, 33534. [CrossRef] [PubMed]
23. Bowles, D.W.; Jimeno, A. New phosphatidylinositol 3-kinase inhibitors for cancer. Expert Opin. Investig. Drugs
2011, 20, 507–508. [CrossRef] [PubMed]
24. Delmore, J.E.; Issa, G.C.; Lemieux, M.E.; Rahl, P.B.; Shi, J.; Jacobs, H.M.; Kastritis, E.; Gilpatrick, T.;
Paranal, R.M.; Qi, J.; et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011,
146, 904–9017. [CrossRef] [PubMed]
25. Reiter, C.E.; Gardner, T.W. Functions of insulin and insulin receptor signaling in retina: Possible implications
for diabetic retinopathy. Prog. Retinal Eye Res. 2003, 22, 545–5462. [CrossRef]
26. Datta, S.R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M.E. Akt phosphorylation of BAD
couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91, 231–241. [CrossRef]
27. Xie, C.; Lu, H.; Nomura, A.; Hanse, E.A.; Forster, C.L.; Parker, J.B.; Linden, M.A.; Karasch, C.; Hallstrom, T.C.
Co-deleting Pten with Rb in retinal progenitor cells in mice results in fully penetrant bilateral retinoblastomas.
Mol. Cancer 2015, 14, 93. [CrossRef] [PubMed]
28. Rogakou, E.P.; Pilch, D.R.; Orr, A.H.; Ivanova, V.S.; Bonner, W.M. DNA double-stranded breaks induce
histone H2AX phosphorylation on serine 139. J. Biol. Chem. 1998, 273, 5858–5868. [CrossRef] [PubMed]
29. Podhorecka, M.; Skladanowski, A.; Bozko, P. H2AX Phosphorylation: Its Role in DNA Damage Response
and Cancer Therapy. J. Nucleic Acids 2010, 2010. [CrossRef] [PubMed]
30. Grasemann, C.; Gratias, S.; Stephan, H.; Schuler, A.; Schramm, A.; Klein-Hitpass, L.; Rieder, H.; Schneider, S.;
Kappes, F.; Eggert, A.; et al. Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p
gains in retinoblastoma. Oncogene 2005, 24, 6441–6449. [CrossRef] [PubMed]
31. Kappes, F.; Damoc, C.; Knippers, R.; Przybylski, M.; Pinna, L.A.; Gruss, C. Phosphorylation by protein kinase
CK2 changes the DNA binding properties of the human chromatin protein DEK. Mol. Cell. Biol. 2004, 24,
6011–6020. [CrossRef] [PubMed]
32. Wise-Draper, T.M.; Allen, H.V.; Jones, E.E.; Habash, K.B.; Matsuo, H.; Wells, S.I. Apoptosis inhibition by
the human DEK oncoprotein involves interference with p53 functions. Mol. Cell. Biol. 2006, 26, 7506–7519.
[CrossRef] [PubMed]
33. Datta, S.R.; Katsov, A.; Hu, L.; Petros, A.; Fesik, S.W.; Yaffe, M.B.; Greenberg, M.E. 14–3-3 proteins and
survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol. Cell 2000, 6, 41–51.
[CrossRef]
Molecules 2018, 23, 1454 14 of 14
34. Sakamaki, J.; Daitoku, H.; Ueno, K.; Hagiwara, A.; Yamagata, K.; Fukamizu, A. Arginine methylation of
BCL-2 antagonist of cell death (BAD) counteracts its phosphorylation and inactivation by Akt. Proc. Natl.
Acad. Sci. USA 2011, 108, 6085–6090. [CrossRef] [PubMed]
35. Zhang, B.; Zhang, Y.; Shacter, E. Rac1 inhibits apoptosis in human lymphoma cells by stimulating Bad
phosphorylation on Ser-75. Mol. Cell. Biol. 2004, 24, 6205–6214. [CrossRef] [PubMed]
36. Renganathan, H.; Vaidyanathan, H.; Knapinska, A.; Ramos, J.W. Phosphorylation of PEA-15 switches its
binding specificity from ERK/MAPK to FADD. Biochem. J. 2005, 390, 729–735. [CrossRef] [PubMed]
37. Moniz, S.; Jordan, P. Emerging roles for WNK kinases in cancer. Cell. Mol. Life Sci. 2010, 67, 1265–1276.
[CrossRef] [PubMed]
38. Lai, J.G.; Tsai, S.M.; Tu, H.C.; Chen, W.C.; Kou, F.J.; Lu, J.W.; Wang, H.D.; Huang, C.L.; Yuh, C.H. Zebrafish
WNK lysine deficient protein kinase 1 (wnk1) affects angiogenesis associated with VEGF signaling. PLoS ONE
2014, 9, e106129. [CrossRef] [PubMed]
39. Sun, X.; Gao, L.; Yu, R.K.; Zeng, G. Down-regulation of WNK1 protein kinase in neural progenitor cells
suppresses cell proliferation and migration. J. Neurochem. 2006, 99, 1114–1121. [CrossRef] [PubMed]
40. Dbouk, H.A.; Weil, L.M.; Perera, G.K.; Dellinger, M.T.; Pearson, G.; Brekken, R.A.; Cobb, M.H. Actions of
the protein kinase WNK1 on endothelial cells are differentially mediated by its substrate kinases OSR1 and
SPAK. Proc. Natl. Acad. Sci. USA 2014, 111, 15999–16004. [CrossRef] [PubMed]
41. Fu, C.A.; Shen, M.; Huang, B.C.; Lasaga, J.; Payan, D.G.; Luo, Y. TNIK, a novel member of the germinal
center kinase family that activates the c-Jun N-terminal kinase pathway and regulates the cytoskeleton.
J. Biol. Chem. 1999, 274, 30729–30737. [CrossRef] [PubMed]
42. Masuda, M.; Uno, Y.; Ohbayashi, N.; Ohata, H.; Mimata, A.; Kukimoto-Niino, M.; Moriyama, H.;
Kashimoto, S.; Inoue, T.; Goto, N.; et al. TNIK inhibition abrogates colorectal cancer stemness. Nat.
Commun. 2016, 7, 12586. [CrossRef] [PubMed]
43. Vizcaino, J.A.; Csordas, A.; del-Toro, N.; Dianes, J.A.; Griss, J.; Lavidas, I.; Mayer, G.; Perez-Riverol, Y.;
Reisinger, F.; Ternent, T.; et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res.
2016, 44, 447–456. [CrossRef] [PubMed]
44. Chou, M.F.; Schwartz, D. Biological sequence motif discovery using motif-x. Curr. Protoc. Bioinform. 2011, 13,
15–24.
45. Horn, H.; Schoof, E.M.; Kim, J.; Robin, X.; Miller, M.L.; Diella, F.; Palma, A.; Cesareni, G.; Jensen, L.J.;
Linding, R. KinomeXplorer: An integrated platform for kinome biology studies. Nat. Methods 2014, 11,
603–604. [CrossRef] [PubMed]
Sample Availability: Samples of the compounds are not available from the authors.
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
